

# External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients

Nina A. Hilken, MD; Linxin Li, MD, DPhil; Peter M. Rothwell, MD, PhD;  
Ale Algra, MD, PhD; Jacoba P. Greving, PhD

**Background and Purpose**—The S<sub>2</sub>TOP-BLEED score may help to identify patients at high risk of bleeding on antiplatelet drugs after a transient ischemic attack or ischemic stroke. The score was derived on trial populations, and its performance in a real-world setting is unknown. We aimed to externally validate the S<sub>2</sub>TOP-BLEED score for major bleeding in a population-based cohort and to compare its performance with other risk scores for bleeding.

**Methods**—We studied risk of bleeding in 2072 patients with a transient ischemic attack or ischemic stroke on antiplatelet agents in the population-based OXVASC (Oxford Vascular Study) according to 3 scores: S<sub>2</sub>TOP-BLEED, REACH, and Intracranial-B<sub>2</sub>LEED<sub>3</sub>S. Performance was assessed with C statistics and calibration plots.

**Results**—During 8302 patient-years of follow-up, 117 patients had a major bleed. The S<sub>2</sub>TOP-BLEED score showed a C statistic of 0.69 (95% confidence interval [CI], 0.64–0.73) and accurate calibration for 3-year risk of major bleeding. The S<sub>2</sub>TOP-BLEED score was much more predictive of fatal bleeding than nonmajor bleeding (C statistics 0.77; 95% CI, 0.69–0.85 and 0.50; 95% CI, 0.44–0.58). The REACH score had a C statistic of 0.63 (95% CI, 0.58–0.69) for major bleeding and the Intracranial-B<sub>2</sub>LEED<sub>3</sub>S score a C statistic of 0.60 (95% CI, 0.51–0.70) for intracranial bleeding. The ratio of ischemic events versus bleeds decreased across risk groups of bleeding from 6.6:1 in the low-risk group to 1.8:1 in the high-risk group.

**Conclusions**—The S<sub>2</sub>TOP-BLEED score shows modest performance in a population-based cohort of patients with a transient ischemic attack or ischemic stroke. Although bleeding risks were associated with risks of ischemic events, risk stratification may still be useful to identify a subgroup of patients at particularly high risk of bleeding, in whom preventive measures are indicated. (*Stroke*. 2018;49:601–606. DOI: 10.1161/STROKEAHA.117.019259.)

**Key Words:** antiplatelet agents ■ bleeding ■ human ■ risk ■ stroke

## See related article, p 513

Lifelong secondary prevention with antiplatelet agents is recommended in patients who experienced a transient ischemic attack (TIA) or ischemic stroke.<sup>1</sup> Bleeding is a clinically important and potentially life-threatening side effect of antiplatelet drugs.<sup>2</sup> Risk of bleeding increases steadily with age, and the gastrointestinal (GI) tract is shown to be the most common source of bleeding.<sup>3–5</sup> Individualized prediction of bleeding risk may help physicians to identify patients at highest risk and may guide treatment decisions regarding initiation of gastroprotective agents.

Recently, the S<sub>2</sub>TOP-BLEED score was developed to predict risk of major bleeding in patients with a TIA or ischemic stroke on antiplatelet agents.<sup>6</sup> The model was derived from individual patient data from 6 randomized clinical trials

(Table I in the [online-only Data Supplement](#)),<sup>7–12</sup> including over 43 000 patients with a TIA or ischemic stroke, and was subsequently validated in the PERFORM trial (Prevention of Cerebrovascular and Cardiovascular Events of Ischaemic Origin With Terutroban in patients With a History of Ischaemic Stroke or Transient Ischaemic Attack Study),<sup>13</sup> including another 19 000 patients with a recent TIA or ischemic stroke.

A potential drawback of using trial data for development of a risk score is that participants may represent a selective subset of the population of interest, as frail and elderly patients are often excluded from trials. As a consequence, absolute risks may be underestimated in a real-world setting and associations between predictors and outcome may differ.<sup>14,15</sup> External validation of a risk score in observational data could, therefore, provide valuable

Received September 4, 2017; final revision received October 31, 2017; accepted November 6, 2017.

From the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (A.A.), University Medical Center Utrecht, Utrecht University, the Netherlands; and Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).

Guest Editor for this article was Tatjana Rundek, MD, PhD.

The online-only Data Supplement is available with this article at <http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.117.019259/-/DC1>.

Correspondence to Nina Hilken, MD, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Internal mail Str 6.131, PO box 85500, 3508 GA Utrecht, the Netherlands. E-mail [n.a.hilken-3@umcutrecht.nl](mailto:n.a.hilken-3@umcutrecht.nl)

© 2018 The Authors. *Stroke* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

*Stroke* is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.117.019259

insight into the accuracy of the predicted risks and the generalizability to a wider range of patients. We aimed to externally validate the S<sub>2</sub>TOP-BLEED score in a population-based cohort and to assess its performance according to site and severity of bleeding. Subsequently, we compared its performance to other risk scores for bleeding in patients with a TIA or ischemic stroke.

## Methods

### Study Population

The OXVASC (Oxford Vascular Study) is an ongoing population-based study on the incidence and outcome of all acute vascular events in Oxfordshire, United Kingdom. Methods and definition of events have been described previously.<sup>16</sup> Briefly, the study population comprises 92 728 individuals, registered with 100 general practitioners in 9 general practices in Oxfordshire. Multiple overlapping methods of hot and cold pursuit are used for ascertainment of all acute vascular events in the study population, which has been shown to be near complete.<sup>17</sup> For the current analysis, we studied patients with a TIA or ischemic stroke between 2002 and 2012, who were on antiplatelet drugs after their event. These included both patients who were on pre-morbid antiplatelet drugs, as well as patients who started antiplatelet drugs after the index event. Patients who switched to oral anticoagulants during follow-up were censored at the time of starting (Table 1 in the [online-only Data Supplement](#)).

Information on patient demographics and vascular risk factors was collected during the initial assessment. Patients were followed-up face to face by a study nurse or physician at 1 month, 6 months, and 1, 5, and 10 years after the index event. Recurrent ischemic events, bleeding events that required medical attention, and disability (modified Rankin Scale) were recorded at each follow-up. Bleeding events were also identified by daily searches of all hospital admissions, by review of administrative diagnostic codes from hospital and primary care records, and by searches of blood transfusion records. Only bleeds that required medical attention or were fatal prior to medical attention could be sought were included. Bleeds secondary to trauma, surgery, or hematological malignancy were excluded.

Bleeds were classified according to site of hemorrhage as either intracranial (intracerebral, subarachnoid, and subdural), upper GI, lower GI, epistaxis, genitourinary, or other. The severity of bleeds was recorded according to the CURE criteria (Clopidogrel in Unstable Angina to Prevent Recurrent Events).<sup>18</sup> Major bleeds were bleeds that were substantially disabling with persistent sequelae, intraocular bleeds leading to significant loss of vision, or bleeds requiring transfusion of  $\geq 2$  units of blood. Major bleeds were classified as life-threatening if the bleeding episode was fatal, symptomatic intracranial, led to a reduction in hemoglobin level of at least 5 g/dL (3.1 mmol/L), led to substantial hypotension requiring use of intravenous inotropic agents, necessitated a surgical intervention, or necessitated transfusion of  $\geq 4$  units of blood. Bleeding events that required medical attention but did not fulfill the criteria of major bleeding were recorded as significant nonmajor bleeds. OXVASC has been approved by the local ethics committee, and all participants gave written informed consent. Requests for anonymized data will be considered by Professor Rothwell (peter.rothwell@clneuro.ox.ac.uk).

### Statistical Analysis

Data were missing on body mass index in 79 patients (4%) and on smoking in 3 patients (<1%). These patients were excluded from the analysis. Variables of the S<sub>2</sub>TOP-BLEED score (Table II in the [online-only Data Supplement](#)) were matched to variables in OXVASC. A proxy was used if no direct match was available. The National Institutes of Health Stroke Scale was used to assess severity of the index event and was used as a proxy for the modified Rankin Scale score, where a National Institutes of Health Stroke Scale score  $\leq 3$  was considered a minor stroke and a score  $>3$  a severe stroke. All patients who received a short course of aspirin plus clopidogrel (for the first 30–90 days) and were treated with aspirin (plus dipyridamole), as our interest was in long term risk of bleeding.

thereafter were analyzed as if they were on aspirin (plus dipyridamole), as our interest was in long term risk of bleeding.

The original regression equation was applied to the validation data to calculate 3-year risk of major bleeding. We assessed discriminatory performance of the model with the C statistic and calibration with the calibration slope and plots. Calibration at 3 years was examined by dividing patients in quintiles according to their predicted risk. The mean predicted risk per quintile group was subsequently plotted against the observed risk per quintile group. Calibration over time was assessed across risk groups that were predefined as low risk (0–10 points on the S<sub>2</sub>TOP-BLEED score), medium risk (11–15 points), and high risk ( $>15$  points).<sup>6</sup> Model performance was also assessed separately by severity of bleeding (nonmajor, major and life-threatening, or fatal) and by site of bleeding (intracranial, upper GI, lower GI, epistaxis, genitourinary, or other). We performed a sensitivity analysis excluding patients with an established high risk of bleeding or reduced life expectancy (patients with renal failure, liver failure, cancer, or a prior peptic ulcer) who are generally not included in trials.

We compared performance of the S<sub>2</sub>TOP-BLEED score with performance of the REACH score for major bleeding,<sup>19</sup> and the Intracranial-B<sub>2</sub>LEED<sub>3</sub>S score (low BMI, high blood pressure, lacune, elderly, Asian ethnicity, cardiovascular disease, cerebrovascular disease, dual antithrombotic treatment or anticoagulant, sex) for intracranial hemorrhage after TIA or ischemic stroke (Table III in the [online-only Data Supplement](#)),<sup>20</sup> by means of the C statistic, integrated discrimination improvement, and net reclassification improvement.<sup>21,22</sup> Another risk score for intracranial hemorrhage after TIA or stroke could not be validated as it required postacute blood glucose levels, which were not available in the validation cohort. To study the influence of the different age categories used in the different risk scores for major bleeding on the performance, we assessed the C statistic of the models containing age only and compared it to the C statistic of the remainder of the model.

As risk factors for bleeding events are also known to be risk factors for recurrent ischemic events, we assessed the discriminatory ability of the S<sub>2</sub>TOP-BLEED score for recurrent ischemic events at 3 years (defined as recurrent ischemic stroke, myocardial infarction, or sudden cardiac death). Next, we assessed the cumulative incidence of bleeding events and recurrent ischemic events at 3 years and their ratio across risk groups of the S<sub>2</sub>TOP-BLEED score. Results are reported in accordance with the TRIPOD statement (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis).<sup>23</sup> All analyses were performed with R version 3.3.2.

## Results

Between 2002 and 2012, 2072 patients with a TIA or ischemic stroke on antiplatelet drugs were included in OXVASC. Median follow-up was 3.5 years (interquartile range 1.5–6.3). Baseline characteristics of patients in the development and validation cohort are shown in Table 1. Patients in OXVASC were older than patients in the CAT trials (Cerebrovascular Antiplatelet Trialists; mean age 73 years [SD, 13.4] versus 66 years [SD 9.7]). Two hundred fifty-four bleeds occurred during follow-up, of which 117 (46%) were major bleeds. Upper GI bleeds were the most common type of bleeding (32%; Table IV in the [online-only Data Supplement](#)). Four hundred sixty-one patients (22%) were classified as having an established high risk of bleeding, and 39% of all major bleeds occurred within this group. Risk of major bleeding was higher in the validation cohort than in the development cohort (Figure 1).

The C statistic of the S<sub>2</sub>TOP-BLEED score for major bleeding was 0.69 (95% confidence interval [CI], 0.64–0.73) and calibration at 3 years was accurate (calibration slope 1.13,  $P=0.48$ ; Figure 2A). Early risk of bleeding was underestimated by the model, but calibration across risk groups was accurate for long term risk of bleeding (Figure 2B). The S<sub>2</sub>TOP-BLEED

**Table 1. Baseline Characteristics of Patients in Development (CAT) and Validation Cohort (OXVASC)**

	OXVASC, N=2072	CAT, N=43 112
Age (mean, SD)	73 (13.4)	66 (9.7)
Female sex	1071 (52)	15 709 (36)
White	2000 (97)	32 756 (76)
BMI (mean, SD)	26.1 (5.5)	26.9 (4.8)
Qualifying event		
Stroke	1177 (57)	38 817 (90)
TIA	895 (43)	4295 (10)
Severity of index stroke		
mRS score 0–2/NIHSS score ≤3	739 (36)	29 826 (69)
mRS score 3–5/NIHSS score >3	438 (21)	8991 (21)
Risk factors and medical history		
Current smoker	307 (15)	9578 (22)
Heavy alcohol use	304 (15)	3577 (8)
Hypertension	1173 (57)	30 406 (71)
Hyperlipidemia	557 (28)	23 219 (54)
Diabetes mellitus	282 (14)	14 373 (33)
Prior stroke	227 (11)	7419 (17)
Prior TIA	189 (9)	5417 (13)
Prior MI	174 (8)	3087 (7)
PAD	138 (7)	2392 (6)
Congestive heart failure	162 (8)	1577 (4)

Values are numbers (percentages) unless otherwise stated. CAT indicates Cerebrovascular Antiplatelet Trialists; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OXVASC, Oxford Vascular Study; PAD, peripheral arterial disease; and TIA, transient ischemic attack.

score was much more predictive for fatal and major bleeding (C statistic 0.77 and 0.69) than for nonmajor bleeds (C statistic 0.50; Table 2). Discriminatory ability was higher for

intracranial and upper GI bleeds than for lower GI bleeds, genitourinary bleeds, and epistaxis (Table 2). A sensitivity analysis excluding patients with an established high risk of bleeding or reduced life expectancy showed comparable discriminatory performance of the S<sub>2</sub>TOP-BLEED score 0.70 (0.64–0.77).


The REACH score showed a C statistic of 0.63 (95% CI, 0.58–0.69) for major bleeding at 2 years and systematically underestimated risk of bleeding (Figure 1A in the [online-only Data Supplement](#)). The Intracranial-B<sub>2</sub>LEED<sub>3</sub>S score had a C statistic of 0.60 (95% CI, 0.51–0.70) for intracranial bleeding at 2 years and showed accurate calibration (Figure 1B in the [online-only Data Supplement](#)). The S<sub>2</sub>TOP-BLEED score showed improved reclassification and integrated discrimination as compared with the REACH and Intracranial-B<sub>2</sub>LEED<sub>3</sub>S scores (Table V in the [online-only Data Supplement](#)).

A model with 5 age categories only as defined in the S<sub>2</sub>TOP-BLEED score (45–54, 55–64, 65–74, 75–85, and 85+) showed a C statistic of 0.66 (0.62–0.71), and a model containing 4 age categories as defined in the REACH score (45–54, 55–64, 65–74, and 75+) had a C statistic of 0.64 (0.60–0.69; Table VI in the [online-only Data Supplement](#)). The predictive performance of the models without age was 0.57 (0.51–0.64) for S<sub>2</sub>TOP-BLEED and 0.52 (0.45–0.58) for REACH.


Four hundred thirty-eight patients experienced a recurrent ischemic event during follow-up, and the overall observed 3-year risk was 19% (95% CI, 17%–21%). The C statistic of the S<sub>2</sub>TOP-BLEED score for predicting recurrent ischemic events was 0.58 (95% CI, 0.55–0.61). Three-year risk of recurrent ischemic events was 15% (95% CI, 12%–17%) in the low bleeding risk group and 23% (95% CI, 16%–30%) in both the medium- and high-risk group (Figure 3; *P* for trend =0.22). The ratio of ischemic events versus bleeds decreased from 7.5:1 in the low-risk group to 2.9:1 in the intermediate-risk group and 1.8:1 in the high-risk group (*P* for trend <0.001).

## Discussion

We externally validated the S<sub>2</sub>TOP-BLEED score for major bleeding in patients with a TIA or ischemic stroke in a population-based cohort and found modest discriminatory performance



**Figure 1.** Cumulative risk of major bleeding in development cohort (CAT) and validation cohort (OXVASC). CAT indicates Cerebrovascular Antiplatelet Trialists; and OXVASC, Oxford Vascular Study.



**Figure 2.** Calibration plots for the S<sub>2</sub>TOP-BLEED score. Calibration plots: 3-year major bleeding-free survival (A) and calibration across risk groups (B). Correspondence between observed and predicted 3-year major bleeding-free survival across quintile groups (A). Observed risk (solid line) and predicted risk (dotted line) across predefined risk groups of the S<sub>2</sub>TOP-BLEED score (B).

and calibration. Compared with the REACH and Intracranial-B<sub>2</sub>LEED<sub>3</sub>S scores, the S<sub>2</sub>TOP-BLEED score showed best performance, both for prediction of intracranial and major bleeds. Although high bleeding risks were also associated with high risks of recurrent ischemic events, risk stratification may still be useful to identify a group of patients at particularly high risk of bleeding, in whom preventive measures are indicated.

Discriminatory performance of the S<sub>2</sub>TOP-BLEED score slightly improved compared with the original development study (C statistic 0.69; 95% CI, 0.64–0.73 versus 0.63; 95% CI, 0.61–0.64). This is likely explained by the fact that the validation cohort is more heterogeneous than the development cohort, as patients were not selected on the basis of strict inclusion and exclusion criteria. In general, external validation studies tend to show a drop in performance of models, often because of overfitting of risk scores in the development data.<sup>15,24</sup> The observation that performance is maintained in a broader setting underlines the robustness of the model and confirms its generalizability to

a wide range of stroke patients. Also, performance of the model is maintained after excluding patients with an established high bleeding risk or reduced life expectancy, showing that the model can help to stratify patients in the group with most uncertainty about the risk of bleeding. Of note, the S<sub>2</sub>TOP-BLEED score performed particularly well for prediction of major and fatal bleeds, which are of clinical importance and may substantially offset the benefit of antiplatelet drugs.

The REACH score systematically underestimated risk of bleeding, which is likely because of the fact that the model was derived from patients with or at risk of atherothrombosis. It has been shown previously that patients with symptomatic vascular disease have higher risks of bleeding than patients with risk factors only.<sup>25</sup> The slightly lower discriminatory performance of REACH compared with S<sub>2</sub>TOP-BLEED can partly be explained by differences in the representation of age in both models, as shown by differences in C statistics for models containing age only. In the REACH score, the weights assigned to age groups imply a linear association between age and bleeding, while the risk of bleeding tends to increase more rapidly at older ages.<sup>5</sup> Also, the elderly patients were not represented separately in the REACH score (the highest category was >75 years), whereas nearly half of all patients with a TIA or stroke are over 75 years of age.<sup>5</sup> Although age was the most important factor in predicting risk of bleeding, other variables in the S<sub>2</sub>TOP-BLEED score do have a relevant contribution to risk prediction, as is shown in Figure II in the [online-only Data Supplement](#); younger patients with multiple risk factors may have higher predicted risk of bleeding than patients in older age groups without additional risk factors.

Although the C statistic improved slightly compared with the development cohort, values below 0.7 are still considered moderately discriminative. However, similar C statistics are seen for bleeding risk scores in other domains, such as for the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly) and ORBIT (older age, reduced haemoglobin/haematocrit/anaemia, bleeding history, insufficient kidney function, treatment


**Table 2. C Statistic (95% CI) of S<sub>2</sub>TOP-BLEED Score in Validation Cohort**

	C Statistic (95% CI)
Severity of bleeding	
Fatal	0.77 (0.69–0.85)
Major (fatal+nonfatal)	0.69 (0.64–0.73)
Nonmajor	0.50 (0.44–0.58)
Site of bleeding*	
Intracranial	0.65 (0.58–0.72)
Upper GI	0.70 (0.64–0.75)
Lower GI	0.51 (0.40–0.62)
Epistaxis	0.43 (0.30–0.55)
Genitourinary	0.53 (0.40–0.67)
Other	0.53 (0.38–0.667)

CI indicates confidence interval; and GI, gastrointestinal.

\*Analyses according to site of bleeding include both nonmajor and major bleeds. Regression equation or risk score included as continuous variable.





**Figure 3.** Cumulative 3-year risk of recurrent ischemic events and major bleeding events across risk groups of the S<sub>2</sub>TOP-BLEED score. Observed 3-year risk of major bleeds and recurrent ischemic events across predefined risk groups of the S<sub>2</sub>TOP-BLEED score.

with antiplatelets) scores in atrial fibrillation.<sup>26,27</sup> Furthermore, calibration of a risk score is as important as its discrimination or may be considered even more important in the current setting, where risk of bleeding has to be weighed against the risk of recurrent ischemic events. We showed that long-term predicted risks accurately corresponded with observed risks. The fact that the model showed good calibration in the validation cohort despite differences in baseline risk and case-mix indicates that variables in the model accounted for most of the differences between the 2 cohorts.

As shown previously, high bleeding risks are associated with high risks of recurrent ischemic events.<sup>28</sup> As such, high estimated bleeding risks cannot easily guide treatment decisions of antiplatelet therapy and should always be accompanied by the assessment of ischemic event risk. However, our results do show that risk of ischemic events stabilizes while risk of bleeding increases in patients in medium- and high-risk groups of the S<sub>2</sub>TOP-BLEED score. Risk stratification may therefore be useful to identify patients in the high-risk group in whom caution seems warranted before starting aggressive dual antiplatelet therapy. Also, estimation of bleeding risk may help to identify patients in whom gastroprotective agents might be indicated. Trials have shown that proton pump inhibitors (PPI) effectively reduce the risk of upper GI bleeding by 70% to 90%,<sup>29</sup> but in clinical practice, proton pump inhibitors are not routinely prescribed, possibly because of concerns over side effects associated with long-term use.<sup>30,31</sup> A recent study has shown that the numbers needed to treat to prevent one upper GI bleed in patients on aspirin are reasonable, particularly in elderly patients (numbers needed to treat 23 to prevent one upper GI bleed at 5 years in patients aged ≥75 years).<sup>5</sup> Co-prescription of proton pump inhibitors may be an effective intervention to lower the risk of GI bleeds, but safety of long-term proton pump inhibitor treatment has not been established in a randomized trial yet. Furthermore, high predicted bleeding risks may trigger physicians to treat and

monitor hypertension more closely, aiming to reduce risk of intracerebral hemorrhages.<sup>32</sup>

Strengths of our study include the population-based nature of the study, the thorough ascertainment of bleeding events through multiple overlapping sources and the long-term follow-up. However, there are also some limitations. Not all variables included in the risk scores were available in the validation cohort, but suitable proxies could be found for most variables. Furthermore, the number of bleeds in the validation cohort was moderate, particularly for the assessment of performance according to site and severity. Last, a small proportion of patients were excluded as they were not prescribed antiplatelet drugs because of recent bleeding or intolerance. However, this reflects clinical practice.

In conclusion, the current study shows that the S<sub>2</sub>TOP-BLEED score can be used to estimate the risk of major bleeding in patients with a TIA or ischemic stroke on antiplatelet drugs. Although the risk of recurrent ischemic events will outweigh the risk of bleeding in the majority of patients, the risk score identifies patients at particularly high risk of bleeding in whom preventive measures should be taken. Future studies may focus on refinement of the S<sub>2</sub>TOP-BLEED score for major bleeding by including results from laboratory tests, such as renal failure and anemia, or radiological characteristics, such as microbleeds. Also, a more thorough assessment of the balance between benefits and risks of long-term antiplatelet drugs is required, incorporating risk estimates on risk of recurrent ischemic events, as well as risk of bleeding.

## Acknowledgments

We are grateful to all the staff in the general practices that collaborated in OXVASC (Oxford Vascular Study): Abingdon Surgery, Stert St, Abingdon; Malthouse Surgery, Abingdon; Marcham Road Family Health Centre, Abingdon; The Health Centre, Berinsfield; Key Medical Practice, Kidlington; 19 Beaumont St, Oxford; East Oxford Health Centre, Oxford; Church Street Practice, Wantage. We also acknowledge the use of the facilities of the Acute Vascular Imaging Centre, Oxford.

## Sources of Funding

The Oxford Vascular Study is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Wellcome Trust, Wolfson Foundation, and British Heart Foundation. Dr Rothwell is in receipt of a NIHR Senior Investigator award. Drs Greving and Hilkens are supported by a grant from the Dutch Heart Foundation (grant number 2013T128). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.

## Disclosures

None.

## References

1. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014;45:2160–2236. doi: 10.1161/STR.0000000000000024.

2. Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009;373:1849–1860. doi: 10.1016/S0140-6736(09)60503-1.
3. Åsberg S, Henriksson KM, Farahmand B, Terént A. Hemorrhage after ischemic stroke—relation to age and previous hemorrhage in a nationwide cohort of 58,868 patients. *Int J Stroke*. 2013;8:80–86. doi: 10.1111/j.1747-4949.2011.00718.x.
4. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. *Lancet*. 2009;374:1967–1974. doi: 10.1016/S0140-6736(09)61751-7.
5. Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. *Lancet*. 2017;390:490–499. doi: 10.1016/S0140-6736(17)30770-5.
6. Hilkens NA, Algra A, Diener HC, Reitsma JB, Bath PM, Csiba L, et al; Cerebrovascular Antiplatelet Trialists' Collaborative Group. Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED. *Neurology*. 2017;89:936–943. doi: 10.1212/WNL.0000000000004289.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*. 1996;348:1329–1339.
8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci*. 1996;143:1–13.
9. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al; MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet*. 2004;364:331–337. doi: 10.1016/S0140-6736(04)16721-4.
10. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706–1717. doi: 10.1056/NEJMoa060989.
11. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet*. 2006;367:1665–1673. doi: 10.1016/S0140-6736(06)68734-5.
12. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al; PROFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med*. 2008;359:1238–1251. doi: 10.1056/NEJMoa0805002.
13. Boussier MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, et al; PERFORM Study Investigators. Ticagrelor versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. *Lancet*. 2011;377:2013–2022. doi: 10.1016/S0140-6736(11)60600-4.
14. Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med*. 2014;11:e1001744. doi: 10.1371/journal.pmed.1001744.
15. Steyerberg EW. *Clinical Prediction Models, A Practical Approach to Development, Validation and Updating*. New York: Springer; 2009.
16. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al; Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet*. 2005;366:1773–1783. doi: 10.1016/S0140-6736(05)67702-1.
17. Coull AJ, Silver LE, Bull LM, Giles MF, Rothwell PM; Oxford Vascular (OXVASC) Study. Direct assessment of completeness of ascertainment in a stroke incidence study. *Stroke*. 2004;35:2041–2045. doi: 10.1161/01.STR.0000137605.48864.2f.
18. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 2001;345:494–502. doi: 10.1056/NEJMoa010746.
19. Ducrocq G, Wallace JS, Baron G, Ravaut P, Alberts MJ, Wilson PW, et al; REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. *Eur Heart J*. 2010;31:1257–1265. doi: 10.1093/eurheartj/ehq021.
20. Amarenco P, Sissani L, Labreuche J, Vicaire E, Boussier MG, Chamorro A, et al; PERFORM and PROFESS Committees and Investigators. The Intracranial-B2LEED3S Score and the risk of intracranial hemorrhage in ischemic stroke patients under antiplatelet treatment. *Cerebrovasc Dis*. 2017;43:145–151. doi: 10.1159/000453459.
21. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med*. 2011;30:11–21. doi: 10.1002/sim.4085.
22. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008;27:157–272; discussion 207. doi: 10.1002/sim.2929.
23. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). *Ann Intern Med*. 2015;162:735–736. doi: 10.7326/L15-5093-2.
24. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. *BMJ*. 2009;338:b605.
25. Alberts MJ, Bhatt DL, Smith SC Jr, Röther J, Goto S, Hirsch AT, et al; REACH Registry Investigators. Risk factors and outcomes for patients with vascular disease and serious bleeding events. *Heart*. 2011;97:1507–1512. doi: 10.1136/hrt.2010.221788.
26. Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. 2010;138:1093–1100. doi: 10.1378/chest.10-0134.
27. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. *Eur Heart J*. 2015;36:3258–3264. doi: 10.1093/eurheartj/ehv476.
28. Matteau A, Yeh RW, Camenzind E, Steg PG, Wijns W, Mills J, et al. Balancing long-term risks of ischemic and bleeding complications after percutaneous coronary intervention with drug-eluting stents. *Am J Cardiol*. 2015;116:686–693. doi: 10.1016/j.amjcard.2015.05.036.
29. Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun X, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. *World J Gastroenterol*. 2015;21:5382–5392. doi: 10.3748/wjg.v21.i17.5382.
30. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. *JAMA Neurol*. 2016;73:410–416. doi: 10.1001/jamaneurol.2015.4791.
31. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA*. 2006;296:2947–2953. doi: 10.1001/jama.296.24.2947.
32. Chapman N, Huxley R, Anderson C, Boussier MG, Chalmers J, Colman S, et al; Writing Committee for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. *Stroke*. 2004;35:116–121. doi: 10.1161/01.STR.0000106480.76217.6f.

## External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients

Nina A. Hilken, Linxin Li, Peter M. Rothwell, Ale Algra and Jacoba P. Greving

*Stroke*. 2018;49:601-606; originally published online February 19, 2018;  
doi: 10.1161/STROKEAHA.117.019259

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231  
Copyright © 2018 American Heart Association, Inc. All rights reserved.  
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/content/49/3/601>

Free via Open Access

Data Supplement (unedited) at:

<http://stroke.ahajournals.org/content/suppl/2018/02/19/STROKEAHA.117.019259.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Stroke* is online at:  
<http://stroke.ahajournals.org/subscriptions/>

**External validation of risk scores for major bleeding in a population-based cohort of TIA  
and ischemic stroke patients**

Nina A Hilkens, MD, Linxin Li, MD, DPhil, Peter M Rothwell, MD, PhD, FRCP, FMedSci,  
Ale Algra, MD, PhD, Jacoba P Greving, PhD

**SUPPLEMENTAL MATERIAL**



## Content

Table I. Characteristics of development cohort (CAT) and validation cohort (OXVASC)

Table II. Score chart of the S<sub>2</sub>TOP-BLEED score

Table III. Overview of REACH, Intracranial-B<sub>2</sub>LEED<sub>3</sub>S and S<sub>2</sub>TOP-BLEED scores

Table IV. Site and severity of bleeds in OXVASC

Table V: Comparison of S<sub>2</sub>TOP-BLEED, REACH and Intracranial-BLEEDS scores

Table VI. Representation of age in risk scores for major bleeding and their performance

Figure I. Calibration of REACH risk score and Intracranial-B<sub>2</sub>LEED<sub>3</sub>S score

Figure II. Predicted three-year risk of major bleeding according to the S<sub>2</sub>TOP-BLEED score per age group

**Table I. Characteristics of development cohort (CAT) and validation cohort (OXVASC)**

	<b>CAT</b>	<b>OXVASC</b>
<b>Source</b>	Trials: CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT, PRoFESS	Population-based cohort
<b>Inclusion criteria</b>	TIA or non-cardioembolic ischaemic stroke	TIA or ischaemic stroke
<b>Inclusion period</b>	1989-2006	2002-2012
<b>Sample size</b>	43,112	2,072
<b>Region</b>	North-America, South-America, Europe, Asia, Australia, South-Africa	Oxfordshire, UK
<b>Outcome</b>	Trial specific definitions of major bleeding	CURE criteria for bleeding
<b>Follow-up, years (median, range)</b>	2.0 (0-8.1)	3.5 (0-10.9)
<b>No of major bleeds</b>	1,530	117

**Table II. Score chart of S<sub>2</sub>TOP-BLEED score for major bleeding<sup>1</sup>**

<b>Factor</b>	<b>Points</b>
Sex - male	2
Smoking - current	1
Type of antiplatelet agent	
Clopidogrel	0
Aspirin (+/- Dipyridamole)	1
Aspirin-Clopidogrel	5
Outcome on mRS 3-5	2
Prior stroke	1
Blood pressure (hypertension)	1
Low BMI	
<20	2
20-25	1
>25	0
Elderly	
45-55	2
55-65	4
65-75	6
75-85	9
>85	12
Ethnicity - Asian	1
Diabetes	1

mRS, modified Rankin Scale

**Table III. Overview of REACH, Intracranial-B<sub>2</sub>LEED<sub>3</sub>S and S<sub>2</sub>TOP-BLEED scores**

<b>Risk score</b>	<b>Study population</b>	<b>Development cohort</b>	<b>Number of bleeds /N</b>	<b>Outcome</b>	<b>Prediction horizon</b>	<b>Included items</b>	<b>Performance in development cohort</b>
<b>REACH<sup>2</sup></b>	Patients with or at risk of atherothrombosis	REACH registry	804/ 56,616	Major bleeding	2 year	Age Smoking Hypertension Diabetes Hypercholesterolemia Peripheral arterial disease Heart failure Antiplatelet agents Oral anticoagulants	0.68
<b>Intracranial B<sub>2</sub>LEED<sub>3</sub>S<sup>3</sup></b>	Patients with TIA or non-cardioembolic ischemic stroke	PERFORM trial	263/ 19,100	Intracranial bleeding	2 year	Age Sex BMI Asian ethnicity Hypertension Cardiovascular disease Cerebrovascular disease Lacune/small vessel disease Dual antiplatelet or oral anticoagulants	0.64 (0.61-0.67)
<b>S<sub>2</sub>TOP-BLEED<sup>1</sup></b>	Patients with TIA or non-cardioembolic ischemic stroke	CAPRIE, ESPS 2, MATCH, CHARISMA, ESPRIT, PRoFESS trials	1530/ 43,112	Major bleeding	3 year	Age Sex BMI Asian ethnicity Smoking Hypertension Diabetes Stroke mRS score Antiplatelet agents	0.63 (0.61-0.64)

**Table IV. Site and severity of bleeding in OXVASC**

	Severity of bleeding				Total, N (%)
	Non-major, N	Major, N	Life-threatening, N	Fatal, N	
Intracranial	0	0	17	19	<b>36 (14%)</b>
Upper GI	35	16	20	10	<b>81 (32%)</b>
Lower GI	26	6	4	1	<b>37 (15%)</b>
Unknown GI	5	3	4	1	<b>13 (5%)</b>
Epistaxis	29	1	1	0	<b>31 (12%)</b>
Genitourinary	29	4	2	0	<b>35 (14%)</b>
Other	13	4	4	0	<b>21 (8%)</b>
<b>Total</b>	<b>137 (54)</b>	<b>34 (13)</b>	<b>52 (20)</b>	<b>31 (12)</b>	<b>254 (100%)</b>

GI gastro-intestinal



**Table V: Comparison of STOP-BLEED, REACH and Intracranial-BLEEDS scores**

	Major bleeding			Intracranial bleeding		
	C-statistic (95% CI)	NRI	IDI	C-statistic (95% CI)	NRI	IDI
S <sub>2</sub> TOP-BLEED	0.69 (0.64-0.73)	0.27	0.006	0.65 (0.58-0.72)	0.39	0.0004
REACH	0.63 (0.58-0.69)	Ref	Ref	-	-	-
Intracranial B <sub>2</sub> LEED <sub>2</sub> S	-	-	-	0.60 (0.51-0.70)	Ref	Ref


CI: confidence interval; NRI: net reclassification improvement; IDI: integrated discrimination improvement; Ref: reference

**Table VI. Representation of age in S<sub>2</sub>TOP-BLEED and REACH scores and their performance**

<b>Risk score</b>	<b>Age groups</b>	<b>Points</b>	<b>C-statistic – age only</b>	<b>C-statistic – overall</b>
<b>S<sub>2</sub>TOP-BLEED</b>			0.66 (0.62-0.71)	0.69 (0.64-0.73)
	45-54	2		
	55-64	4		
	65-74	6		
	75-84	9		
	≥85	12		
<b>REACH</b>			0.64 (0.60-0.69)	0.63 (0.58-0.69)
	45-54	0		
	55-64	2		
	65-74	4		
	≥75	6		

**Figure I. Calibration of REACH score and Intracranial B<sub>2</sub>LEED<sub>3</sub>S score**

**A**



**B**





Figure Legend: Calibration of REACH score for two-year risk of major bleeding in OXVASC (A) and calibration of Intracranial-B<sub>2</sub>LEED<sub>3</sub>S score for two-year risk of intracranial haemorrhage in OXVASC (B)

**Figure II. Predicted three-year risk of major bleeding according to the S<sub>2</sub>TOP-BLEED score per age group**



## References

1. Hilkens NA, Algra A, Diener HC, Reitsma JB, Bath PM, Csiba L, et al. Predicting major bleeding in non-cardioembolic stroke patients on antiplatelets: S2TOP-BLEED. *Neurology* 2017;89:936-943.
2. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. *Eur Heart J*. 2010;31:1257-1265.
3. Amarenco P, Sissani L, Labreuche J, Vicaud E, Bousser MG, Chamorro A, et al. The intracranial-B2LEED3S score and the risk of intracranial hemorrhage in ischemic stroke patients under antiplatelet treatment. *Cerebrovasc Dis*. 2017;43:145-151.